Gyala Therapeutics, a spin-off of Hospital Clínic de Barcelona, received a EUR 1.5m investment from Invivo Ventures.
Gyala Therapeutics, based in Barcelona, is engaged in developing new CAR-T therapies for the treatment of malignant hematological diseases.
